Diabetes Surge Drives Novo Nordisk To Expand Organically In Emerging Markets As Sanofi Moves To Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
An expected surge in the number of diabetic patients has prompted the world’s biggest insulin manufacturer to build up resources in emerging markets, most recently unveiling its largest overseas R&D center, while rival Sanofi eyes acquisitions.
You may also be interested in...
Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity
BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia 2014: Distribution, Manufacturing To The Fore
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.